Muscle Preservation on GLP-1 Medications: What the Science Says You Need to Do

Here is a number worth sitting with: men using semaglutide or tirzepatide for weight loss can lose roughly 10 percent or more of their skeletal muscle mass over a 68- to 72-week treatment period. Researchers reviewing the clinical evidence put that figure in stark perspective — it is approximately equivalent to 20 years of normal, age-related muscle loss compressed into little more than a year. For men who started GLP-1 therapy to get healthier, stronger, and leaner, that is a sobering trade-off that deserves serious attention.

GLP-1 receptor agonists have genuinely transformed obesity medicine. Drugs like semaglutide and tirzepatide produce weight loss in the range of 15 to 24 percent of body weight in clinical trials, with meaningful downstream improvements in blood pressure, blood glucose, cholesterol, and cardiovascular risk. A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society called these medications genuinely transformative — while also flagging muscle and bone loss as one of the most clinically significant challenges that needs to be proactively managed. The medication works. But without the right nutritional and training strategy running alongside it, a meaningful portion of what you lose will not be fat.

Understanding why this happens — and what you can actually do about it — is the difference between using a GLP-1 as a fat loss tool and accidentally using it as a muscle loss tool.

Why GLP-1 Medications Put Muscle at Risk

The mechanism is not complicated, even if the biology underneath it is. GLP-1 receptor agonists work primarily by suppressing appetite and slowing gastric emptying, which dramatically reduces caloric intake. That caloric deficit is what drives the weight loss. But the human body under significant energy restriction does not distinguish cleanly between fat tissue and lean tissue when it starts breaking down mass for fuel. Research published in Metabolism: Clinical and Experimental found that over 25 percent of total weight lost during incretin-based pharmacotherapy typically comes from fat-free mass — a category that includes skeletal muscle, bone, and other lean tissue. That mirrors what has been documented with bariatric surgery, which achieves comparable rates of weight loss and comparable rates of lean mass loss.

The researchers behind that analysis also pointed to a biological system that becomes critically relevant during rapid weight loss: the myostatin-activin-follistatin-inhibin axis. In states of significant negative energy balance, activins and myostatin — proteins that promote muscle degradation — become more active, while follistatin, which normally counters their effects, loses ground. The result is a biochemical environment that is actively hostile to muscle retention. Emerging compounds like bimagrumab and trevogrumab are being studied specifically to block this pathway, but those are years away from widespread clinical use. What is available right now, and what the evidence strongly supports, is combining resistance training and adequate protein intake with GLP-1 therapy from day one.

There is another layer to this problem that gets less attention than it deserves: the downstream consequences of muscle loss do not end when you stop the medication. A 2024 narrative review in Diabetes Care made the point that lean mass losses during incretin therapy are comparable in magnitude to a decade or more of normal aging — and that when patients stop the medication, weight regain predominantly comes back as fat rather than muscle. Men who lose significant lean mass during their GLP-1 cycle and then discontinue the drug are left with a worse body composition than when they started, not just a return to baseline. That risk makes the case for proactive muscle preservation not just a performance consideration but a metabolic health imperative.

The Two Non-Negotiables: Protein and Resistance Training

The clinical consensus across multiple expert bodies and peer-reviewed analyses converges on two interventions that have the strongest evidence for preserving muscle mass during GLP-1-driven weight loss: adequate dietary protein and structured resistance exercise. These are not optional add-ons. The 2025 strategies review in Obesity Reviews stated explicitly that all patients receiving incretin-mimetic drugs for obesity should participate in comprehensive treatment programs emphasizing both adequate protein and micronutrient intake alongside resistance training — full stop.

Protein is the raw material your muscle tissue needs to survive caloric restriction. Under normal eating conditions, hitting 0.7 to 1 gram of protein per pound of body weight is a reasonable target for active men. On a GLP-1 medication, where appetite suppression can make eating difficult and total caloric intake drops substantially, this becomes much harder — and much more important. The risk is not just eating less protein in absolute terms; it is that protein becomes a smaller fraction of an already reduced intake unless you are deliberate about prioritizing it. High-quality protein sources — lean meats, eggs, Greek yogurt, cottage cheese, whey protein — need to anchor every meal, even when appetite is suppressed and those meals are small. The 2025 joint advisory from Mozaffarian and colleagues specifically flagged nutrient deficiencies from calorie reduction as a key challenge of GLP-1 therapy, recommending baseline dietary screening and active nutrition counseling as part of any treatment program.

On the training side, the evidence is equally direct. Locatelli and colleagues found that supervised resistance exercise training programs lasting more than ten weeks produce increases in lean mass of approximately three kilograms and strength gains of around 25 percent in men and women — gains that directly counteract the lean mass losses associated with incretin therapy. This is not about being in the gym five days a week. Two to three well-structured resistance training sessions per week, prioritizing compound movements that challenge the major muscle groups — squats, deadlifts, rows, presses — provide the anabolic stimulus that tells your body muscle is still needed and worth preserving. Without that signal, the body has no compelling reason not to sacrifice muscle tissue when energy intake is restricted.

The same review from Diabetes Care also noted that combining aerobic exercise with liraglutide improved long-term weight loss maintenance compared with either intervention alone — suggesting the benefits of exercise alongside GLP-1 therapy extend beyond just the acute phase of weight loss to the sustainability of results over time. This matters enormously for men who intend to eventually taper or stop the medication. The muscle and metabolic fitness you build during treatment becomes your buffer against rebound.

What the Body Composition Data Actually Shows

It is worth being precise about what GLP-1 medications do and do not do to body composition, because the picture is more nuanced than the headlines often suggest. A 2025 review in Current Opinion in Endocrinology, Diabetes, and Obesity found that while GLP-1 receptor agonists do cause absolute reductions in lean body mass, relative preservation or even improvement in lean mass proportion is observed in some analyses — meaning the ratio of muscle to fat in the body can actually improve even as total lean mass declines slightly. The drugs also appear to preferentially reduce visceral adipose tissue, the metabolically dangerous fat stored around the organs, which is arguably the most important target for improving metabolic health in men with obesity.

The same review found that resting energy expenditure — the number of calories your body burns at rest, which tends to drop during aggressive caloric restriction — is largely maintained during GLP-1 therapy, with some studies even reporting increases during prolonged treatment. That is a genuinely encouraging finding, because metabolic rate suppression is one of the primary mechanisms through which caloric restriction diets fail men long-term. Rodent studies cited in that review also pointed to direct protective effects of GLP-1 receptor activation on muscle tissue through anti-inflammatory and myogenic pathways, suggesting the medications may have some intrinsic muscle-protective properties beyond simply reducing body weight. This does not eliminate the need for protein and training — but it does suggest the situation is not as dire as the raw lean mass loss numbers might initially imply, provided men are putting in the work to support their musculature.

The picture changes significantly at medication cessation. The data on what happens when GLP-1 therapy stops is consistent and sobering: weight regains, and it regains primarily as fat. Men who have preserved or built muscle during their treatment period are in a substantially better position post-cessation than those who lost significant lean mass — both because muscle increases basal metabolic rate and because it represents a functional, structural reserve that fat does not. This is the long game, and it is one that favors men who treat the medication as a catalyst for building better habits rather than a passive solution.

The Takeaway

GLP-1 medications are powerful tools for fat loss and metabolic health — but they are tools, not complete strategies. The research is unambiguous that without adequate protein intake and consistent resistance training, a substantial portion of what you lose on these medications will be the muscle you need for long-term health, function, and body composition. The men who get the best outcomes from GLP-1 therapy are not the ones who simply take the injection and wait. They are the ones who treat the appetite suppression as an opportunity to eat fewer calories while prioritizing protein density, who build or maintain a resistance training practice throughout the treatment period, and who understand that the medication is setting the stage for a healthier body — one they still have to build. The science gives you the roadmap. What you do with it is up to you.